Form 4: Alector CEO Arnon Rosenthal Granted 116,246 RSUs

Alector, Inc. CEO Arnon Rosenthal received a grant of 116,246 restricted stock units, vesting in two tranches in 2026 and 2027.

Summary

• Arnon Rosenthal, Chief Executive Officer and Director of Alector, Inc., was granted 116,246 restricted stock units (RSUs) on March 13, 2026.
• These RSUs will vest in two equal installments: 50% (58,123 shares) on September 1, 2026, and the remaining 50% (58,123 shares) on March 1, 2027.
• Following this transaction, Mr. Rosenthal directly beneficially owns 2,454,422 shares of Common Stock.
• Mr. Rosenthal also indirectly beneficially owns 1,972,875 shares through The Rosenthal Family Revocable Trust, and 652,500 shares each through the Adi Rosenthal 2007 Trust, Noam Rosenthal 2007 Trust, and Shani Rosenthal 2007 Trust, for a total of 3,930,375 indirect shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment and alignment of the CEO with the company's long-term performance through equity incentives.

Positives

• The grant of restricted stock units to the CEO aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a common practice to attract and retain executive talent, signaling confidence in the company's future.

Future Outlook

The vesting schedule for the granted restricted stock units indicates future equity compensation events for the CEO on September 1, 2026, and March 1, 2027, linking executive incentives to future company performance.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align executive incentives with long-term shareholder value creation, a common practice among Alector's peers in the competitive biopharma landscape.

Comparison to Industry Standards

• Equity compensation for executives, particularly through RSUs, is a widely adopted practice across the biotechnology sector, including companies like Biogen, Regeneron, and Amgen.
• The structure of vesting over several years is typical, aiming to retain key talent and incentivize sustained performance.
• While the specific number of units granted varies based on company size, executive role, and performance metrics, the mechanism observed here is consistent with global benchmarks for executive remuneration in growth-oriented industries.

Related Party Transactions

• The indirect beneficial ownership through The Rosenthal Family Revocable Trust and the Adi, Noam, and Shani Rosenthal 2007 Trusts are related party transactions, as the Reporting Person serves as trustee for these trusts.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term shareholder value.
• Management: Increased equity stake and long-term incentive for the CEO.

Next Steps

• Vesting of 50% of the granted RSUs on September 1, 2026.
• Vesting of the remaining 50% of the granted RSUs on March 1, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to the CEO, which is a standard compensation practice and generally viewed as a neutral to slightly positive event for aligning management incentives. It does not provide new fundamental information that would warrant a change in investment recommendation, hence a 'hold' is appropriate.

Keywords

Alector, ALEC, Arnon Rosenthal, CEO, Restricted Stock Units, RSUs, Equity Compensation, Insider Transaction, Form 4, Beneficial Ownership